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Abstract Current detection methods (computed tomog-
raphy, ultrasound, and MRI) for hepatocarcinogenesis in
humans rely on visual confirmation of neoplastic forma-
tions. A more effective early detection method is needed.
Using in vivo magnetic resonance spectroscopy (MRS), we
show that alterations in the integral ratios of the bis-allyl
to vinyl hydrogen protons in unsaturated lipid fatty acyl
groups correlate with the development of neoplastic for-
mations in vivo in a TGFa/c-mycmouse hepatocellular carci-
noma (HCC) model. HPLC analysis of the TGFa/c-myc
mice liver tissue revealed a significant increase in the
amount of oleic acid, along with alterations in linoleic and
g-linolenic acids, as compared with control CD1 mice. Elec-
trospray ionization tandem mass spectrometry analysis in-
dicated a significant increase in the abundance of specific
glycerol phosphatidylcholine (GPCho) lipids containing pal-
mitic and oleic acids between control CD1 and TGFa/c-myc
mice liver tissue extracts. Western blot analysis of the mice
liver tissue indicates alterations in the desaturase enzyme
stearoyl CoA desaturase (SCD)1, responsible for palmitic
and oleic acid formation. Microarray analysis detected alter-
ations in several genes involved with fatty acid metabolism,
particularly SCD2, in transgenic mouse liver tissue. In
correlation with the HPLC, mass spectrometry, Western blot,
and microarray analyses, we are able to confirm the ability
of in vivo MRS to detect precancerous lesions in the mouse
liver before visual neoplastic formations were detectable by
MRI.—Griffitts, J., Y. Tesiram, G. E. Reid, D. Saunders, R. A.
Floyd, and R. A. Towner. In vivo MRS assessment of altered
fatty acyl unsaturation in liver tumor formation of a TGFa/
c-myc transgenic mouse model. J. Lipid Res. 2009. 50: 611–622.
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Hepatocellular carcinoma (HCC) is one of the most
deadly forms of cancer in the world. The World Health
Organization reports that liver cancer is the third highest
cause of death from cancer, with HCC being predominantly
observed in Asian and African countries (1). There are
many known causes of HCC, including hepatitis B and C,
cirrhosis, and aflatoxin exposure. The techniques currently
used for diagnosis of liver cancer rely on imaging modali-
ties (MRI, computed tomography, and ultrasound) that, at
the highest sensitivity, are able to detect evidence of neopla-
sia when there is a formation of at least 1 mm. Image con-
firmation of a neoplasm this size usually only occurs at a
later stage in cancer development when therapy treatments
are not as effective. Therefore, the prognosis for a patient
when they have visual evidence of neoplasia is poor. Ad-
ditionally, neoplasms at the lower range of imaging detec-
tion are often unverifiable without biopsy. There is a need,
therefore, to develop a method that can detect neoplastic
formations at an earlier stage than those now in use.
The efficacy of utilizing MRI, which mainly detects only
protons from water hydrogens, for hepatic tumor detec-
tion and the measurement of tumor volumetric growth
has been established previously (2, 3). We have utilized
MRI in this study for visual confirmation of neoplastic tis-
sue formations in the TGFa/c-myc mouse liver tumor
model. In addition to the MRI visible liver changes, there
have been several metabolic alterations in lipid processes
and composition noted in association with HCC. Alter-
ations in cholesterol have been shown to occur, with de-
creases in cholesterol coinciding with patient mortality
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(4). It has been reported that glycerol phosphatidyletha-
nolamine (GPE) increases in concentration in hepatocyte
nodules resulting in a decreased glycerol phosphatidyl-
choline (GPCho)/GPE ratio (4).
The main components of phospholipids, fatty acids, are
known to have effects in cellular signaling. Fatty acids are
involved in apoptosis and cell-cycle regulation (4, 5). Fatty
acid synthesis along the v-6 pathway results in the produc-
tion of prostaglandins and leukotrienes that are an integral
part of the apoptotic pathway (4, 6). Certain desaturase en-
zymes involved in fatty acid synthesis such as stearoyl-CoA
desaturase (SCD) and fatty acid desaturase 2 (FADS2 or D6
desaturase), are known to contribute to high oleic and
low g-linolenic acid levels, respectively, in hepatoma cells
(4, 7). Abel et al. (4) found that the levels of MUFA were
increased in rat hepatocyte nodules over time. The PUFA
g-linolenic has been noted to have anticancer effects in
cells with an increase in lipid peroxidation leading to
apoptosis of the cells (6, 8). The observation of metabolic
alterations in the fatty acid profile of the liver in vivo would
seem to be a valid technique to utilize for hepatocarcino-
genic nodules and tumors.
Magnetic resonance spectroscopy (MRS), which can be
used to assess hydrogen-containing molecules other than
water as observed by MRI, has been used in numerous
studies to identify alterations in metabolites associated with
various cancers (9–12). MRS has also been used to quan-
tify levels of total choline compounds in the human breast
as a diagnosis tool for suspicious lesions (9). It has been
previously established using single-voxel MRS, that
changes in the lipid profiles of tumor tissue during the
stages of development are observable with proton MRS
(13). Alterations in the methyl and methylene hydrogens
from lipid resonances were noted using MRS (13). The
Foley et al. (13) study also showed that there were in-
creases in the unsaturated methylene hydrogens found
in PUFA at 2.8 ppm and increases in the unsaturated lipid
olefinic hydrogens at 5.4 ppm during hepatocarcino-
genesis. Previous research in our lab has shown the ability
of two-dimensional spectroscopy to characterize PUFA spe-
cies from the resonances at 2.8 and 5.3 ppm (14). In this
study, we wanted to determine the efficacy of utilizing MRS
to measure the degree of unsaturation (DU) of the bis-allyl
and vinyl lipid hydrogens at 2.8 and 5.3 ppm, respectively,
in association with nodule and tumor development in a
TGFa/ c-myc transgenic HCC model in vivo. Our work
has shown that by taking a ratio of the integral values of
the peaks of the lipid hydrogens at 2.8 ppm and 5.3 ppm,
we can determine the DU of the fatty acids in tissue lipids.
Ex vivo smooth muscle research by Singer et al. (11) also
utilized the ratio of methylene protons between sites of
unsaturated protons for determining the DU. He et al.
(10) also looked at the lipid signals resonating at 2.8 and
5.3 ppm in a human breast cancer study.
Chemical shift imaging (CSI) is a MRS technique where
multiple voxels in a grid pattern acquire metabolic infor-
mation across a wide area inside a tissue of interest. Each
of the voxels in a CSI scan produces a separate and unique
spectrum apart from its neighbor. Essentially, CSI detects
in vivo the tissue distributions of metabolites (10). CSI
has been utilized to monitor biochemical and metabolic
phenotypic changes noninvasively in animals and humans
(10, 15–17). CSI has also been utilized to detect intra-
cranial mobile lipids in the rat brain utilizing an ultrashort
echo time (TE) (18). Another study showed promise in
the use of CSI as a noninvasive method of differentiating
malignant skeletal tumors from nonmalignant tissue (19).
In this study, we wanted to determine the efficacy of uti-
lizing MRS CSI to measure the DU of the bis-allyl and vinyl
lipid hydrogens at 2.8 and 5.3 ppm, respectively, in associa-
tion with nodule and tumor development in a TGFa/
c-myc transgenic HCC model in vivo. We have found that
an alteration in this DU value correlates with liver neopla-
sia in a transgenic mouse model of hepatocarcinogenesis.
METHODS
Animal model
A transgenic mouse model of hepatocarcinogenesis was used
as the experimental model in this study (n 5 20). These trans-
genic mice have mutations in the transcriptional regulator c-myc
as well as the cell growth factor TGFa (20, 21). The transgenic
mice develop a primary form of liver cancer that has many similar
features to that observed in humans (20, 21). CD1 mice were
used as the nontransgenic controls in this study (n 5 6). All mice
were routinely monitored for any signs of discomfort or severe
illness. Animal weights were taken at each of the MRI/MRS anal-
ysis time points; there was no correlation between the changes in
the animalʼs body weight and the onset of neoplastic formations.
Mice were euthanized using CO2 gas asphyxiation. Liver tissue
was immediately removed from the mice upon euthanasia. Liver
tissue sections were removed from the tumorous regions in the
transgenic mice at the time of sacrifice of the animals and sent
for histologic preparation. H and E stains of the liver tissue were
performed. The experiments were carried out in conformity with
NIH policy and with the Oklahoma Medical Research Founda-
tionʼs Institutional Animal Care and Use Committee approval.
MRI and MRS
All of theMRI andMRS data were collected on a Bruker Biospec
7.0 Tesla/ 300MHz small animal 30 cm horizontal bore spectrom-
eter USR 70130(Oklahoma City, OK). The analysis time points
for this study were 20, 26, 30, 34, and 40 weeks of age for the con-
trol and transgenic mice. There were five transgenic mice scanned
at 40 weeks of age; 15 transgenic mice were scanned at 34 weeks;
20 transgenic mice were scanned at 20, 26, and 30 weeks. Each
transgenic mouse was scanned more than once in the MRI and
MRS study, up to its time of sacrifice in the time point study.
The same six control mice were scanned at each time point of
the study and then sacrificed at the last time point of 40 weeks.
At least five transgenic mice were sacrificed at each time point
for in vitro analysis and additional control mice were purchased
for in vitro tissue analysis at all time points. A multirung bird-cage
coil was utilized in this study. A gradient echo fast low angle shot
scan was utilized to obtain the 12 multislice images of the mice,
with a TE of 5.35 ms, a relaxation time (TR) of 189.12ms, a flip
angle of 60°, eight averages, a 2563 256 matrix, spatial resolution
of 150 mm, and a total acquisition time of 8 min. The field of view
on all scans was 38.4 mm3 38.4 mmwith a slice thickness and slice
gap both of 1 mm. 1H-MRS data were obtained, utilizing MRI
images for anatomical positioning, with a CSI scan. Parameters
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for the CSI scan were: a TE of 3.5 ms, a TR of 1,500 ms, water sup-
pression, a 38.4 mm 3 38.4 mm field of view, and an acquisition
time of 30 min. A total of 1,024 scans were taken and averaged
together for each MRS scan. A matrix of 323 32 voxels, or regions
of interest (ROIs), were used to obtain multiple spectra from all
areas of a single centrally located 1.5 mm thick slice in the liver.
During MRI/MRS analysis, the animals were anesthetized using
2-3% Isoflurane and 100% oxygen respiration was constantly
monitored using a respiration pillow and SAM PC gating software
(SAI Instruments, Manchester, England). To process the data, the
software program Mathematica was utilized. Magnitude spectra
processed by Paravision software was imported into Mathematica.
A ratio of the bis-allyl to vinyl hydrogen protons near unsaturated
bonds in fatty acids was taken to produce the DU measurement
(12). Using Mathematica, we were able to correlate the MRS data
of DU values with a corresponding MRI anatomical image.
Lesions that were visually apparent on MRI images at 34 and
40 weeks of age were correlated with CSI data sets of spectra. ROIs
were selected at earlier time points (20, 26, and 30 weeks) in the
CSI data sets corresponding to regions of MRI apparent lesions at
34 and 40 weeks. The curve in Fig. 3 was generated utilizing pure
standards and was based off of previously published work in our
lab (12).
HPLC
The lipids were extracted from liver tissue of the transgenic
and control mice at various time points, following a modified
Folch extraction method where a 2:1 chloroform to methanol
mixture with 0.01% butylated hydroxytoluene was used to extract
the lipids after tissue homogenization, and a sodium sulfate filled
funnel was used to remove excess water (22). The various lipid
classes in the liver sample were separated by thin layer chromatog-
raphy (TLC) utilizing a mobile phase of 50:25:8:4 chloroform/
methanol/glacial acetic acid/water v/v. Individual GPCho and
GPE lipids were removed from the TLC plates, saponified, and
the subsequent separated fatty acids were then esterified to pro-
duce fatty acid phenacyl-esters (23). The phenacyl-ester extracts
were analyzed for alterations in the fatty acid profile using a gra-
dient HPLC method utilizing a 75:25 v/v HPLC grade acetonitrile
to water ratio as mobile phase A, and 100% acetonitrile as mobile
phase B. A reverse phase LC-18 250 3 4.6 mm column (Supelco)
was used, and absorbance of the fatty acids was detected with a
UV/Vis detector at 242 nm. Peak areas were measured for each
fatty acid of interest in the chromatogram. Studentʼs t-test of inde-
pendent samples was performed for all analyses. Data values are
displayed as mean 6 SE. Solvents were all filtered HPLC grade,
purchased from Honeywell Burdick and Jackson (Morristown,
NJ). Pure standards for oleic, linoleic, g-linolenic, and arachidonic
acids were purchased from Sigma-Aldrich (St. Louis, MO). Pure
standards were used to determine retention times of the indi-
vidual fatty acids, and a standard curve of each pure fatty acid
standard was obtained. These standards were chosen for this study
due to their high levels in hepatocytes and for their possession of
unsaturated bonds of importance to this study.
nESI-MS and MS/MS
Lipids were extracted from 200 mg liver tissue of the trans-
genic and control mice at 30 weeks, following a modified Folch
extraction method where a 2:1 chloroform/methanol mixture
was used to extract the lipids after tissue homogenization, and
a sodium sulfate filled funnel was used to remove excess water
(22). Lipid extracts were then dried under a stream of N2 and
stored at 270°C prior to analysis. Dried lipid extracts were resus-
pended in 500 ml of methanol/chloroform (1:1 v/v), then aliquots
were diluted 1:20 in isopropanol/methanol/chloroform (4:2:1 v/v)
containing 20 mM NH4OH and 1.6 mM 1,2-ditetradecanoyl-sn-
glycero-3-phosphocholine (GPCho(14:0/14:0)). Samples were then
introduced to a Thermo Fisher model TSQ Quantum Ultra triple
quadrupole mass spectrometer (San Jose, CA) via a chip-based
nano-electrospray ionization (nESI) source (Advion NanoMate,
Ithaca, NY) operating in infusion mode using an ESI HD chip
A, a spray voltage of 1.4 kV, a gas pressure of 0.3 psi, and an air
gap of 2ml. The ion transfer tube of the mass spectrometer was
maintained at 150°C. All MS and MS/MS spectra were acquired
automatically by methods created using the Xcalibur software
(Thermo Fisher, San Jose, CA). In MS mode, the Q1 peak width
was maintained at 0.5 Th. For precursor ion (PI) MS/MS scans,
Q1 was operated at a peak width of 0.4 Th, while Q3 was main-
tained at 0.5 Th. For product ion scan mode MS/MS experiments,
Q1 and Q3 were operated with peak widths of 1.0 Th. The Q2 col-
lision gas pressure was set at 0.5 mtorr. MS and MS/MS scans were
typically acquired using scan rates of 500 m/z second21. Collision
energies were individually optimized for each lipid class-specific
product ion or PI scan mode MS/MS experiment.
Identification of GPCho lipids was initially achieved using a
lipid class specific PI scan mode experiment to monitor for the
characteristic phosphocholine product ion at m/z 184 (PI 184).
Then, assignment of the acyl substituents present in each of
the identified GPCho lipids was based on correlation with the
information provided from specific PI scan mode MS/MS spectra
in negative ion mode (for example, PI 283 and PI 327 to monitor
for lipids containing 18:0 and 22:6 fatty acyl chains, respectively),
and by the use of product ion scan mode MS/MS experiments in
negative ion mode at the specific m/z values at which individual
[M1Cl]- GPCho lipids were observed.
Quantitative analysis of changes in GPCho lipid abundances
that occurred between control and transgenic liver mouse liver
tissue was achieved by measurement of changes in the abundance
of the characteristic GPCho specific m/z 184 product ion for a
given precursor ion, compared with that of the GPCho(14:0/14:0)
internal standard, after manual correction for isotope contribu-
tions. Where more than one GPCho lipid was found to be present
at a given m/z value, quantification was based on the combined
relative abundances of the fatty acid anions that were observed
in the negative ion mode MS/MS spectra. Note that characteriza-
tion of the fatty acyl chains in the lipids identified here was re-
stricted to determination of the total number of carbons and
double bonds, and that information regarding their relative sites
of attachment to the glycerol backbone, and the specific position
of the double bonds, was not obtained. Some previous studies
have suggested that the relative abundances of lipid ions ob-
served under ESI conditions are concentration dependent, and
also highly influenced by the acyl chain length and DU (24).
More recently this effect has been characterized to occur under
conditions of high total lipid concentration. At low concentra-
tions, a linear correlation of ion intensity with the lipid concen-
tration of each class is observed (25–28). In this study, although
we did not know a priori the absolute concentration of the lipid
extracts, mass spectra of each lipid extract were initially acquired
at a range of different dilutions to determine the dilution range
at which linearity in the response of specific lipids was observed.
This was done in order to ensure that the ratio of specific lipid
ion abundances compared with other lipids within the mixture,
or compared with an internal standard, remained constant. We
report here only the relative change in the abundance of the ex-
perimentally observed GPCho lipid against that of the internal
standard and not the absolute concentrations of the control and
transgenic mice groups to avoid ESI response difference errors.
MS/MS spectra shown were typically acquired for a period of
2.5–10 min. A five-point Gaussian smooth was applied to all spec-
tra prior to data analysis. Studentʼs t-test of dependent samples
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was performed for all analyses. Data values are displayed as
mean 6 SD. All solvents used were filtered HPLC grade. Metha-
nol (MeOH) was purchased from J.T. Baker (Phillipsburg, NJ).
Hydrochloric acid (HCl), ammonium hydroxide (NH4OH),
and chloroform (CHCl3) were from EMD Chemicals (Gibbstown,
NJ). Synthetic phospholipid standards were purchased from
Avanti Polar Lipids Inc. (Alabaster, AL).
Western blots
Proteins were extracted from the transgenic and control liver
tissues using a radio immuno precipitation assay buffer and sepa-
rated using sodium dodecyl sulfate-polyacrylimide gel electro-
phoresis (SDS-PAGE) gels. A nitrocellulose membrane (0.45 mm
pore size) was used for transfer of the proteins. Antibodies against
SCD1, FADS2, and fatty acid desaturase 1 (FADS1) were utilized
for enzyme expression detection. Visualization of the proteins
was achieved by 5-bromo-4-chloro-3-indolyl phosphate/nitro
blue tetrazolium labeling of alkaline phosphatase secondary anti-
bodies. The SCD1 antibody was a mouse monoclonal (Santa Cruz
Biotechnology, Inc., Santa Cruz, CA), and the FADS2 antibody
was a rabbit anti-mouse polyclonal antibody (Alpha Diagnostic
International, San Antonio, TX). The FADS1 antibody used was
a rabbit anti-human polyclonal antibody (ProteinTech Group,
Inc., Chicago, IL).
Microarray
RNA was isolated from the liver tissue and further purified
using an RNeasy Mini Kit (Qiagen, Valencia, CA) and the RNA
cleanup protocol provided. After purification, the RNA concentra-
tion was determined with a Nanodrop scanning spectrophotome-
ter, and then qualitatively assessed for degradation using the ratio
of 28:18s rRNA obtained from a capillary gel electrophoresis system
(Agilent 2100 Bionalalyzer, Agilent Technologies).
The Illumina TotalPrep™ RNA Amplification Kit was used
for labeling cRNA (Ambion, Austin, TX). Briefly, 200 ng of total
RNA was primed with T7-oligo-dT and reverse transcribed, fol-
lowed by production of double-stranded cDNA with E. coli DNA
polymerase. cRNA was transcribed in vitro from the T7 promoter
using a biotinylated ribonucleotide analog. cRNA was hybrid-
ized to HumanRef-8 v2 Expression BeadChips as specified by
Illumina (San Diego, CA). BeadChips were washed and stained
according to the Illumina protocol and scanned with an Illumina
BeadArray Reader.
Illumina BeadStudio software was used to quantitate the sig-
nal from BeadChips, and the MATLAB normalized values were
imported into BRB ArrayTools (Biometric Research Branch,
National Cancer Institute) where they were then log transformed.
Genes that fell below the 50th percentile of gene variance were
excluded from the results. We identified genes that were differen-
tially expressed between any two classes by using a multivariate
permutation test (29, 30). We used the multivariate permutation
test to provide amedian false discovery rate (FDR) of 5% (90% con-
fidence). The test statistics used were random variance t-statistics
for each gene (31). Genes that were differentially expressed
(,5% FDR) and simultaneously had a ratio 2-fold or larger were
used in further analyses.
Pathways were explored by placing the data of genes that only
passed our significance/ratio threshold into Ingenuity Pathways
Analysis (Ingenuity: Systems, www.ingenuity.com).
Statistical analysis
Statistical analysis of the data produced by the various experi-
ments was performed, utilizing a Studentʼs t -test of independent
samples between control and transgenic mice at each time point.
Two-way ANOVA (GraphPad Prism 5 software, La Jolla, CA) was
used to determine significant changes between control and trans-
genic mice over the time course assessed. A difference was assessed
between the control and transgenic mice peak area values for each
fatty acid in question and the ANOVA was then applied.
RESULTS
Histology and MRI results
Histological analysis of the tissue from the transgenic mice
reveals small but noticeable nodules forming at 30 weeks of
age in the male mouse liver tissue (Fig. 1A). There was slight
steatosis and nuclear pleomorphism noticeable in the nod-
ules of these 30-week-old mice. At 40 weeks of age in these
mice, rampant nodular and tumor growth was observed in the
liver sections with severe nuclear pleomorphism accompa-
nied with steatosis and loss of liver lobule structure (Fig. 1C).
MRI images of the transgenic mice showed the development
of nodules in two males at 26 weeks of age and three other
males at 30 weeks of age; all other animals had evidence of
nodular formations at later time points (Fig. 2A). The mini-
mal lesion size was a 2.7 3 2.4 mm nodule at 26 weeks of
age. A plot of tumor volume growth shows an exponential
increase for the transgenic mice, compared with no de-
tected tumors for control CD1 mice (Fig. 2B). A significant
difference (P , 0.03) was found between transgenic mice
at 30 weeks compared with transgenic mice at 40 weeks of
age. Pathologic analysis of histology slides was able to con-
firm the neoplasms noted in the MRI images.
MRS results
A relationship of the 2.8 to 5.3 ppm MRS detectable
lipid peaks to the number of double bonds in fatty acyl
groups is illustrated in Fig. 3. The curve was generated
Fig. 1. Histological sections of liver tissue from TGFa/ c-myc mice
at (A) 30, (B) 34, and (C) 40 weeks of age respectively highlighting
the nodular regions in the tissue. Note the occurrence of nuclear
pleomorphism and steatosis as early as 30 weeks (A). CD1 control
liver tissue section at 40 weeks of age (D).
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using pure fatty acid standards. In Fig. 3, a decrease in the
R value corresponds to a decrease in the number of dou-
ble bonds in the fatty acids. This relationship can be ex-
plained by the formula:
n bonds 5 21/(R21)
In this formula, the number of bonds is equal to the re-
ciprocal value of R (2.8 ppm peak divided by the 5.3 ppm
peak) minus 1, because R can never be more than 1 (12).
The average R value for the transgenic mice at each
experimental time point is plotted on the graph (depicted
by the diamond shape). The R values of the transgenic
mice indicate that as the mice age, the fatty acids in the
liver are predominantly monounsaturated (nbonds 5 1).
Fig. 4A depicts a representative spectrum from the MRS
data that was obtained from a selected ROI that corre-
sponded to tumor development in TGFa/ c-mycmice. From
MRS analysis a significant decrease in the DU, 2.8 ppm peak
(2CH 5 CH2CH22CH 5 CH2)/5.3 ppm peak (2CH 5
CH2), of the fatty acyl groups in the lipids was revealed
over time (Fig. 4B). Fig. 4B was generated utilizing averages
of DU values for each of the animals at a particular time
point. Measurements were obtained from the spectra if
the peak of interest was at least five times the baseline noise.
The CD1 control and TGFa/c-myc transgenic mice began
with a DU close to 0.45 at 20 weeks, which represents a high
level of linoleic acid (Fig. 3). By 26 weeks, there was a sig-
nificant (P, 0.001) difference between the DU of the con-
trol mice and the DU in the transgenic mice. At subsequent
time points, the DU in the transgenic mice decreased to an
end point of 0.1, which represents a high level of oleic acid
(Fig. 3). Meanwhile, the control mice remained relatively
constant in their DU, maintaining an average value of 0.4.
By the 40-week time point, there was a noticeable differ-
ence in the spectra of transgenic versus control mice, with
the bis-allyl 2.8 ppm peak (representative of fatty acids with
more than one double bond) becoming generally much
smaller in the transgenic mice compared with controls
(Fig. 5). Two-way ANOVA analysis of the transgenic and
control mouse DU values revealed a significant difference
(P, 0.05). To eliminate any bias in voxel selection, we aver-
aged DU values in a 42 voxel region in a neoplastic region
and nonneoplastic region of transgenic and control mice.
Fig. 6 illustrates our voxel averaging findings in a 30-week-
old transgenic mouse. The sixteen voxel average DU values
of the neoplastic region were 0.298, while the average DU
value for the nonneoplastic region was 0.424.
HPLC and mass spectrometry results
HPLC analysis of the liver tissues removed from the
transgenic and control mice at each of the MRS time
points revealed alterations in the amounts of several fatty
Fig. 3. The relationship of the 2.8 ppm to 5.3 ppm ratio (R) of
lipid peaks, detected by magnetic resonance spectroscopy (MRS)
to the number of double bonds (nbonds). Note that as the R de-
creases so does nBonds. The integral ratio values of the TGFa/
c-myc mice from the study are also plotted on the line with the data
points identified by their age in weeks (from 20 to 40 weeks). The
integral ratio values of the TGFa/ c-myc mice indicate that as they
get older, the fatty acids tend to be predominately monounsatu-
rated (nBonds 5 1), such as in oleic acid.
Fig. 2. A: Representative MR images (single slices from multiple
slice data sets) of the liver regions of TGFa/ c-myc mice at 20 (i),
26 (ii), 30 (iii), 34 (iv), and 40 (v) weeks, depicting the develop-
ment of nodules (iii) and tumors (iv and v). A comparative repre-
sentative image of a control CD1 mouse liver at 40 weeks is also
displayed (vi). Outlined regions depict nodules and/or tumors.
B: Liver tumor volumes measured from multiple MRI image slices
taken through the livers of TGFa/ c-myc mice and CD1 mice from
20 to 40 weeks of age (N 5 5 animals per time point). The large
variability is attributed to the data sets being a combination of male
and female tumor volumes. The females developed neoplasia much
later than the males. Error bars represent mean 6 SD.
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acids in the PC fraction (Fig. 7A). Plots are shown as aver-
ages 6 SE. From 20 to 40 weeks in the transgenic mice,
there is an increasing trend of the MUFA oleic acid as
was observed in the CD1 controls (Fig. 7Ai). However, over
time, the amount of oleic acid in the transgenic mice re-
mains above that of the control mice. Two-way ANOVA
comparison of the oleic acid levels in the control and trans-
genic mouse liver tissue revealed a significant difference
(P , 0.005). Alterations in the PUFAs linoleic, g-linolenic,
and arachidonic acids occurred (Fig. 7Aii, iii, iv). These
PUFAs had a decreasing trend in the transgenic mice over
time from 20 to 40 weeks of age, while the control mice
showed a gradual increase over time. A significant decrease
from 20 to 40 weeks was noted in linoleic (P , 0.005),
g-linolenic (P , 0.05) and arachidonic (P , 0.05) acids.
If a ratio of the PUFA to MUFA from the glycerol PC frac-
tion is taken from the HPLC data, a decreasing correlation
similar to the MRS ratio of the 2.8:5.3 ppm peaks appears
(Fig. 4B) for the transgenic mice (Fig. 7B). Average PUFA/
MUFA values of the MUFA oleic acid and combined PUFAs
linoleic, g-linolenic, and arachidonic acids from each ani-
mal were used to form the graph in Fig. 7B. HPLC analysis
of individual unsaturated fatty acid peak areas indicated an
absence of any notable alterations at any time point in fatty
acids from the PE fraction of the transgenic and control
mouse livers.
Electrospray ionization (ESI), coupled with the use of
tandem mass spectrometry (MS/MS) experiments in a tri-
ple quadrupole (QqQ) mass spectrometer, revealed signifi-
cant changes in the abundances of the GPCho-16:0/18:1
lipid species between the crude liver tissue extracts of
30 week control (n 5 4) and transgenic (n 5 3) animals
(Fig. 8). The complementary information provided from a
GPCho lipid class specific PI scan MS/MS experiment, to
monitor the formation of a characteristic phosphocholine
Fig. 6. MR image of a 30-week-old mouse with an apparent neo-
plasm with 42 average degree of unsaturation (DU) (or R) values,
obtained using chemical shift imaging (CSI), of the nodular and
nonnodular regions displayed. The DU of the nodular region is
much lower than the nonnodular region and is similar to the aver-
age DU value of transgenic mice found for the 30-week time point
as shown in Figure 4B. The nonneoplastic DU value is similar to what
was observed for the average control mice DU value at 30 weeks in
Figure 4B.
Fig. 5. Representative spectra from transgenic (A) and control
(B) mice at 40 weeks of age. The vinyl (5.3 ppm), bis-allyl
(2.8 ppm), water (4.7 ppm), and methyl (0.5–1.0 ppm) peaks are
indicated on the spectra. Note the difference in the bis-allyl peak at
2.8 ppm between the two mice.
Fig. 4. A: MR image (left) of a TGFa/ c-myc mouse at 40 weeks
with tumors highlighting the region of interest (ROI) that the spec-
trum (right) was obtained from. This ROI represents a single voxel
in the 32 3 32 matrix of voxels. Each ROI contains a unique spec-
trum. Spectra for the determination of the R were taken from vox-
els located centrally in a nodule or tumor region. The vinyl and
bis-allyl proton peaks are highlighted on the spectrum. B: Average
R values of TGFa/ c-myc and control mice at each time point com-
piled from spectra such as in panel A (n 5 5 animals per time
point). Note that as the TGFa/ c-myc mice age, the R decreases.
This contrasts with the CD1 mice, which have a relatively constant
R throughout the study. Of importance is that at 26 weeks, when
there are relatively no MRI observed nodules, there is a significant
difference in the R between the TGFa/ c-myc mice and the CD1
control mice. This illustrates that MRS is more sensitive than MRI
and could detect alterations in the R of the fatty acids that are in-
dicative of hepatocellular carcinoma (HCC) associated neoplastic
lesions. Error bars represent mean 6 SD.
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product ion at m/z 184 (PI 184) in positive ion mode, as
well as fatty acyl group specific PI MS/MS scans or product
ion MS/MS scan experiments in negative ion mode, were
employed to elucidate the identity of the head group, as
well as the identities of the fatty acyl chains (number of
total carbons and double bonds), within the lipid of inter-
est. For these samples, an internal standard consisting of a
GPCho(14:0/14:0) lipid was added prior to mass spectrome-
try analysis. Quantification was achieved by measurement
of changes in the abundance of the experimentally ob-
served GPCho lipid abundance against that of the internal
standard, for the control and transgenic mice groups. A
.2-fold change (P . 0.05) was observed in the abundance
of the GPCho(16:0/18:1) lipid (m/z 760.3), while a .1.5-fold
change [P. 0.05 (i.e., not significant)] was observed in the
abundance of GPCho(16:0/22:6) (m/z 806.3). Although as-
sessed there were no significant differences in GPE lipids
(data not reported).
Western blot results
Western blot analysis of the male transgenic and male
control mouse liver tissue was performed. A Studentʼs t -test
of independent values revealed there was a significant in-
crease in SCD1 (P , 0.05) at the 34-week time point in the
Fig. 7. A: HPLC analysis of fatty acyl species from the glycerol phosphatidylcholine (GPCho) fraction of phospholipids found in the trans-
genic (■) and control (♦) mouse liver tissue revealed several altering trends in oleic (i), linoleic (ii), g-linolenic (iii), and arachidonic (iv)
fatty acids. Results are shown as averages of n $ 3 animals/time point for the transgenic mice and n 5 3 animals/time point for the control
mice 6 SE. There was a gradual increase in oleic acid (A) over time based off of HPLC analysis (R2 5 0.4069). There was a greater amount
of oleic acid in the transgenic mice (■) at all time points over the control mice (♦). A decreasing trend for linoleic acid (B) was observed in
the transgenic mice (■) from 20 to 40 weeks of age upon HPLC analysis of the liver tissue (R2 5 0.7851). This trend is directly opposite of
what is seen in the control mouse liver tissue (♦). There was an overall decrease in g-linolenic acid (C) from 20 to 40 weeks of age in the
transgenic mice (■) as opposed to control mice (♦) based off HPLC analysis (R2 5 0.6731). Arachidonic acid (D) amounts for the trans-
genic mice (■) decresed from 20 to 40 weeks of age in the transgenic mice (R2 5 0.1473), while there was a gradual increase in arachidonic
acid observed in the control mice (♦). B: The ratio of PUFA to MUFA based off of the HPLC data sets shows a decreasing trend similar to the
MRS ratio of the 2.8:5.3 ppm peaks (Figure 4B) appears for the transgenic mice (■). This indicates that the level of PUFAs is decreasing
over time while the MUFA levels are increasing. The control mouse (♦) trend indicates a greater increase in PUFAs over MUFA from 20 to
40 weeks of age. Results are shown 6 SE.
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transgenic mice compared with the control mice (Fig. 9).
Representative images of the blots from the 40-week time
point are included in Fig. 9. FADS2 enzyme levels, respon-
sible for g-linolenic acid formation, remained stationary
over time in the transgenic mice, while the control mice
FADS2 levels were shown to gradually increase from 20
to 40 weeks of age, although there was no significant dif-
ference between transgenic and control mice at any time-
point or over the time-course studied (data not shown).
Although an increasing trend of FADS2 levels in transgenic
mice at 20 weeks of age is present, the increase was found
to be not significant (P . 0.05). FADS1 (D5 desaturase),
responsible for the formation of arachidonic acid, showed
no significant alteration in enzyme levels over time in the
transgenic versus control mice (data not shown).
Microarray results
Microarray analysis of male transgenic and male control
tissue at 30 weeks, with a 3-fold change and 5% false discov-
ery rate (FDR), presented us with several interesting find-
ings regarding lipid metabolism. Three of the top six
canonical pathways affected in the transgenic versus con-
trol data set were related to lipid metabolism. For the
purposes of this study we focused solely on the lipid metab-
olism pathways. The top canonical pathway affected in the
transgenic mice when compared with controls is that of
linoleic acid metabolism (P 5 7.89E-07). Some of the up-
regulated genes associated with this pathway are several
members of the cytochrome P450 (CYP) family, involved
in fatty acid and xenobiotics metabolism in the liver,
including CYP2B9, CYP2B13, and CYP2C18 (Fig. 10A).
There were many down-regulated genes associated with
linoleic acid metabolism including: CYP2C37, CYP2C50,
CP2C54, CYP2D13, CP4A22, CP4F8, and PNPLA3. Ara-
chidonic acid metabolism was another highly affected ca-
nonical pathway (fourth overall) when comparing the
transgenic and control mice (P 5 1.33E–04). The same
genes affected in linoleic acid metabolism were also in-
volved in the alterations in arachidonic acid metabolism.
The desaturase enzyme SCD2 was found to be up-regulated
(3-fold) in the transgenic tissue as compared with the con-
trol tissue with an exponential value of 12.200 (Fig. 10B).
This enzyme is involved in the formation of oleic acid from
stearoyl-CoA.
DISCUSSION
The findings of this study have shown that MRS is able to
detect in vivo alterations in phospholipid unsaturated fatty
acyl hydrogens in a transgenic mouse model of HCC that
correlates with neoplastic lesion formation. Significant
alterations in the levels of unsaturated of fatty acyl lipids
were noted as early as 26 weeks of age in the transgenic
mice, a time point where MRI, the standard diagnostic
imaging technique, was only able to detect neoplasms in
a few cases. Coinciding with the MRS results, we have cor-
roborating experimental evidence utilizing other methods
(HPLC, ESI-MS/MS, Western blot, and microarray) that
showed there were hepatocarcinogenesis-associated al-
terations in the unsaturated fatty acids, desaturase enzyme
levels, and gene expression. MRS was able to detect a sig-
nificant difference (P , 0.001) in the DU of the fatty acids
of lipids in the liver at a time point (26 weeks) before there
were any significant detectable lesions (e.g., nodules or
tumors) by MRI in almost all of the transgenic animals,
compared with CD1 control mice. The MRS CSI method
was used to establish where in the liver the DU ratio was
lowest. In most of the transgenic mice (.95%), these re-
gions of low DU coincided with MRI detection of visual
nodules or tumors that appeared at later time points.
The spectra used to determine the DU value were taken
from the same anatomical ROI at each time point. The
anatomical ROI was determined by using MRI images of
the TGFa/c-myc mouse livers at stages where visually ap-
Fig. 7.—Continued.
Fig. 8. Quantitative ESI-MS/MS analysis of glycerol phosphatidyl-
ethanolamine (GPE) lipids in the crude liver tissue extracts of
30-week control (n 5 4) and TGFa/ c-myc (n 5 3) mice. A .2-fold
change (* P . 0.025, one-tailed t-test with pooled estimation of
variance) was observed in the abundance of GPCho(16:0/18:1)
(m/z 760.3), (measured as the change in ratio of GPCho(14:0/14:0) /
GPCho(16:0/18:1) between the control and TGFa/ c-myc mice
groups), while a .1.5-fold change (P . 0.05, one-tailed t -test with
pooled estimation of variance) was observed in the abundance of
GPCho(16:0/22:6) (m/z 806.3).
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parent nodular or tumor growth was observed. We then
backtracked through earlier time points, selecting the
same ROI in the animals at each time until we selected a
time and corresponding ROI with no visual neoplastic
lesions in the MRI images. By moving forward in time,
we could conceivably use the decreased DU ratios to pre-
dict where a neoplastic formation would occur.
The HPLC results support our MRS data, where in the
transgenic mice there is an increase in the level of the
MUFA oleic acid and decreases in the levels of the PUFAs
linoleic, g-linolenic, and arachidonic acids over time dur-
ing neoplastic growth development. The ESI-MS/MS re-
sults from lipids extracts obtained at 30 weeks revealed
an increase in the abundance of certain GPCho lipids con-
taining palmitic and oleic acids. We chose to utilize the
30-week time point for ESI-MS/MS analysis of the liver tis-
sue to try and clarify what changes are occurring at this
juncture, because we observed an increase in neoplastic
formations by MRI and histology in many of the transgenic
mice at this time. Conversely, the HPLC results showed no
significant alterations in unsaturated lipids between the
transgenic and the control groups at 30 weeks. We postu-
late that the lack of detectable changes in the unsaturated
fatty acyl PCs in the transgenic and control mice at the
30 week time point is due to decreasing levels occurring in
the transgenic mice while there is are increasing levels in
the CD1 controls resulting in a cross-over being reached
in the fatty acid levels between both groups at this time-
point (Fig. 7A).
With the MRS data, we are measuring the peak areas
of the bis-allyl or allylic methylene hydrogen protons at
2.8 ppm (2CH22CH22CH5; found only in PUFAs) and
the vinyl or olefinic methylene hydrogen protons at 5.3 ppm
(2CH5 CH2; found in all unsaturated fatty acids, but the
only peak that would be seen in MUFA) of mobile lipids.
A related recent study in humans was conducted using a
MR spectroscopic imaging method to determine the levels
of PUFAs in cancerous breast tissues, where they found that
decreased PUFA levels were present in an invasive ductal
carcinoma of a breast cancer patient compared with
healthy breast tissue (32). In that study selective multiple-
quantum coherence transfer was used to detect the same
lipid hydrogens that we used to calculate a DU ratio in
our mouse study, which were the bis-allyl hydrogen protons
of the unsaturated acyl chain at 2.8 ppm coupled to the
vinyl hydrogen protons of PUFA at 5.3 ppm (32).
In our study, when we compared the PUFA values taken
from the HPLC data to the MUFA values, we observed a
correlation similar to the MRS ratio of the bis-allyl to vinyl
protons. The measurements in the MRS data are from
ratio comparisons of hydrogen atoms (the methylene hy-
drogens between the double bonds, compared with the
vinyl hydrogens on the double bonds) on unsaturated fatty
acyl groups of mobile lipids, and not direct measurements
of the relative amount of hydrogen atoms in individual un-
saturated fatty acyl lipid groups. As such, while we are mea-
suring all fatty acyl groups of mobile lipids in the sampling
window, we are taking a ratio value that reflects alterations
in MUFA and PUFA levels associated with nodule and
tumor formation. Changes in individual molecular species,
as was obtained in the HPLC and ESI-MS/MS data sets,
reflect differences that may not directly correspond to
the MRS data. However, the HPLC and ESI-MS/MS results
can be used to correlate with the in vivo MRS analysis for
overall fatty acyl lipid composition. We observed a signifi-
cant change in unsaturated fatty acyl lipid ratios in the
MRS data during hepatocarcinogenesis, which directly cor-
related to comparative alterations in HPLC and ESI-MS/
MS data.
Tying in with the HPLC measurement of fatty acid lev-
els, the Western blot data for some desaturase enzymes,
particularly SCD1, involved in the synthesis of unsaturated
fatty acids also had corresponding changes. From the West-
ern blot data on FADS2 enzyme levels we noticed some al-
teration from 20 to 40 weeks of age in the transgenic mice
when compared with controls; however, it was not signifi-
cant. It is believed that impairment in FADS2 function
would result in an increase in FA substrates, such as oleic
Fig. 9. Western blot analysis for stearoyl CoA desatu-
rase (SCD) enzyme levels reveals that a ratio of the
optical density of SCD bands to b-actin loading con-
trol bands shows a gradual increase in SCD levels
over time in the transgenic mice (dark bars) while
the SCD levels in the control mice (light bars) re-
main relatively constant over time. Representative
images of the Western blots from the 40 week time
point are shown for the transgenic (T) and control
(C) mouse liver tissue. Results are shown as an aver-
age of n $ 3 animals/time point 6 SE.
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acid (4). Indeed, the findings of our study show an in-
crease in oleic acid levels. The increased SCD level ob-
served in the Western blots (Fig. 9) in the transgenic
tissue, when compared with the control tissue, supports
the findings that there is an increase in oleic acid in the
transgenic mice, particularly at week 34. The results of
the Western data for SCD1 at week 34 support our HPLC
and MRS results, which indicate an increase of MUFA (as
observed from MRS data), such as oleic acid (as observed
from HPLC and ESI-MS/MS data).
Interestingly, in our microarray analysis of the tissue,
there were many genes seen to be either up-regulated or
down-regulated in the transgenic mice when compared
with the controls. One noted change related to fatty acid
metabolism was in SCD2, a desaturase enzyme involved in
oleic acid formation, which is more highly expressed in
Fig. 10. A: Pathway analysis of isolated RNA from transgenic (n 5 3), compared with control liver (n 5 3) tissue, at 40 weeks revealed
up-regulation (depicted by a red color) and down-regulation (depicted by a green color) in several genes involved in lipid metabolism with
a 3-fold difference and 5% false discovery rate (FDR). B: Pathway analysis of isolated RNA from transgenic (n 5 3), compared with control
liver (n 5 3) tissue, at 40 weeks of age. The c-myc gene is mutated in the transgenic mice and leads to an up-regulation of several genes. The
most notable increase in relation to unsaturated lipid metabolism is SCD2 with a 3-fold increase in transgenic mice compared with controls
and 5% FDR.
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embryonic liver. The significance of this finding is that
SCD2 expression in the adult normal liver is much lower
at 40 weeks in comparison to embryonic liver. It would ap-
pear that SCD2 may be partly responsible for the increase
in MUFA oleic acid in the transgenic liver tissue, as de-
tected by microarray analysis, along with SCD1, as detected
by Western blots. Pathway analysis of the microarray data
reveals that SCD2 is directly acted upon and upregulated
by c-myc. The mutation and subsequent increase in c-myc
expression in our mice would lend to the increase in
SCD2 up-regulation.
We utilized the CSI method to obtain our spectra in or-
der to overcome one of the common arguments against
MRS as a diagnostic tool, the fact that traditional MRS ob-
tains only a single spectrum from one region of the liver.
With CSI, we are able to obtain a series of unique spectra
from different spatial regions in a 1.5 mm thick slice of the
liver in order to look for any alterations in the fatty acid
profile in heterogeneous tissue. One drawback to CSI is
the effect known as chemical shift drift, which occurs when
the peaks in spectra adjacent to one another have a grad-
ual shift in the position of the metabolites, resulting in
some metabolites not being in the correct position on
the ppm scale. In order to overcome this drawback, the
center most spectrum in the CSI matrix was determined
and a correction formula was applied to all spectra that
adjusted the ppm scale accordingly. The main focus of this
study was to show the ability of MRS to detect in vivo alter-
ations in the DU of fatty acyl groups from lipids in the
livers of transgenic mice that developed neoplasia. Addi-
tional MRS analysis could identify specific species of fatty
acyl groups of lipids in vivo, but that would involve using
2-dimensional (1H and 13C) MRS methods requiring dif-
ferent RF coils other than were utilized in this study and
potentially longer acquisition times.
Overall, we have shown that MRS can be used to detect
alterations in lipid metabolism associated with hepatocar-
cinogenesis in the mouse liver in vivo before nodules or
tumors are visually seen with MRI in most cases. There
was a significant difference in the DU between the trans-
genic mice and control mice at 26 weeks of age while there
were MRI visible lesions noted at this time point in only
two animals out of 20. HPLC, Western blot, and microarray
data all support our MRS findings with correlative alter-
ations in the expression of MUFA and PUFA noted by all
of the corroborating experiments. The usefulness of MRS
in providing early detection metabolic information associ-
ated with primary liver cancer in mice is evident and the
application of similar methods to clinical studies should be
further pursued.
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